Ligand Reports Second Quarter 2026 Financial Results
Ligand Pharmaceuticals reported robust second quarter 2026 financial results with a 32% year-over-year growth in royalty revenue, raising the low end of its adjusted EPS guidance while maintaining revenue guidance. The company completed a $700 million zero-interest convertible debt financing and finalized the acquisition of XOMA Royalty, significan…